Wharton's jelly MSCs
Cells from donated umbilical cords, sold as younger and stronger than your own. The supply chain runs through tissue banks and offshore clinics, not an approved product.
Availability Offered in select countries
What it is
Wharton's jelly is the gel that cushions the vessels inside an umbilical cord, donated after healthy births. It is unusually rich in mesenchymal stem cells. Two very different things are sold from it: whole tissue processed into an injectable allograft, and cells cultured out of that tissue and expanded in a lab.
Why people choose this treatment
The pitch is donor age. These cells come from day one of a life rather than from a sixty-year-old hip, and clinics lean hard on that contrast. It also skips the marrow aspiration, which makes it an easier sell than banking or using your own.
How it's delivered
Two markets, and the difference matters. In the United States, clinics inject birth-tissue allografts into a joint under a tissue-bank label. Offshore clinics in Antigua, Mexico, and Panama culture-expand living cells and infuse them intravenously. Only the second involves cells that are reliably still alive.
Where the evidence stands
No Wharton's jelly product has FDA approval, and the FDA's position is that culture-expanded cell products are unapproved drugs. A 2025 systematic review of knee osteoarthritis pooled six studies covering 97 patients: function scores improved, imaging results were mixed, no severe adverse events. None of those studies had a placebo arm. The randomized trial against hyaluronic acid and saline is still running. Safety is not theoretical: in 2018 the CDC documented twelve patients hospitalized with bloodstream and joint infections from contaminated umbilical cord blood products.
Estimated cost
- $4,000–$10,000 per joint, US birth-tissue allograft tier
- $15,000–$35,000 for a systemic course in Antigua
- $4,500–$8,000 Mexico clinic tier
- Travel on top; not covered by insurance
Who offers it
Observed at the Stem Cell Medical Center in Antigua and across the Mexico and Caribbean tier, and at US practices selling birth-tissue allografts for joints. Ask which of the two products you are actually buying.
Observed in provider menus on our last research pass; each listing is stamped when verified. We may be compensated when you contact providers through Longevity.io; payment never affects ranking.
Go deeper
The full guide, Stem Cell Therapy for Longevity and Recovery, separates approved uses from the offshore market and explains what a tissue-bank label does and does not certify.
Longevity.io is for educational purposes only and is not medical advice. Whether a cord-derived cell product belongs in your plan is a conversation for a clinician who knows your situation, and one worth having before you book travel. Confirm eligibility, services, and pricing directly with any provider.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
